Bruker BioSciences (BRKR)

The Bruker BioSpin Company, or after the merger, BRKR, intends to retain a significant stake in the superconducting wire business, but does not need to be a sole owner of that business and will open it up in 2008 to additional investors.

Let me continue on slide 15 and give you an outlook of the Bruker Corporation that we hope will emerge after the closing, after the combination of Bruker BioSciences as it exists today and the Bruker BioSpin Group that is being acquired in this transaction. There is a shared history and common culture and common values here. There is a strong commitment to research and development, to innovation, to growth, to intellectual property. We’re close to our customers and have attained leading market positions in many key segments.

The combined company is expected to benefit from some rather attractive, but also diversified markets. We see significant synergies in growing markets. We benefit from better leverage on the overall strong Bruker brand recognition among customers. And we believe that the combined Bruker Corporation after the closing will also be positioned for further margin improvement and accelerating cash flow.

Slide 16 gives you a historical overview of the various Bruker companies. I will not go through this, but anticipate and hope that in 2008 we will combine the Bruker BioSciences and Bruker BioSpin into the Bruker Corporation after the closing expected in the first quarter of 2008. The planned Bruker Corporation, as you see on slide 17, will be a global life science research and analytical system solutions company, truly with critical mass in distribution around the globe.

Slide number 18 gives you some financial highlights. I will not go into the details; I think those speak for themselves, and you can certainly take a look at them at your convenience. They are also mentioned briefly in our press release. But as promised at the beginning of this presentation, the focus today will not be financial. We will get into more detailed financial pro forma numbers once we have filed our preliminary proxy.

5

The Bruker BioSpin Company, or after the merger, BRKR, intends to retain a significant stake in the superconducting wire business, but does not need to be a sole owner of that business and will open it up in 2008 to additional investors.

Let me continue on slide 15 and give you an outlook of the Bruker Corporation that we hope will emerge after the closing, after the combination of Bruker BioSciences as it exists today and the Bruker BioSpin Group that is being acquired in this transaction. There is a shared history and common culture and common values here. There is a strong commitment to research and development, to innovation, to growth, to intellectual property. We’re close to our customers and have attained leading market positions in many key segments.

The combined company is expected to benefit from some rather attractive, but also diversified markets. We see significant synergies in growing markets. We benefit from better leverage on the overall strong Bruker brand recognition among customers. And we believe that the combined Bruker Corporation after the closing will also be positioned for further margin improvement and accelerating cash flow.

Slide 16 gives you a historical overview of the various Bruker companies. I will not go through this, but anticipate and hope that in 2008 we will combine the Bruker BioSciences and Bruker BioSpin into the Bruker Corporation after the closing expected in the first quarter of 2008. The planned Bruker Corporation, as you see on slide 17, will be a global life science research and analytical system solutions company, truly with critical mass in distribution around the globe.

Slide number 18 gives you some financial highlights. I will not go into the details; I think those speak for themselves, and you can certainly take a look at them at your convenience. They are also mentioned briefly in our press release. But as promised at the beginning of this presentation, the focus today will not be financial. We will get into more detailed financial pro forma numbers once we have filed our preliminary proxy.

5